Evidence map›Paper›PMID 41280912›Full record

ArticleFrontiers in immunology2025

Defined metabolic states shape T cell fate and function across culture conditions.

Kayla Sylvester, Natasha Karassina, Anthony C Lauer, Gediminas Vidugiris, Jolanta Vidugiriene

Abstract read
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Kayla SylvesterResearch and Development, Promega Corporation, Madison, WI, United States.
Natasha KarassinaResearch and Development, Promega Corporation, Madison, WI, United States.
Anthony C LauerResearch and Development, Promega Corporation, Madison, WI, United States.
Gediminas VidugirisResearch and Development, Promega Corporation, Madison, WI, United States.
Jolanta VidugirieneResearch and Development, Promega Corporation, Madison, WI, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: T cell metabolism is a key determinant of immune function and therapeutic efficacy, yet current expansion protocols often neglect how culture conditions influence metabolic programming. We employed a modular, low-input bioluminescent assay platform to profile how media, activation strength, and metabolic perturbation define metabolic trajectories that persist through early expansion and influence downstream outcomes. Methods: A multifactorial experimental design was used to evaluate early T-cell activation across media (ICXF, TexMACS, RPMI+FBS) and activators (TransAct, Dynabeads, ImmunoCult). Low-input bioluminescent assays were used to quantify metabolic cofactors (ATP, NAD Results: By measuring intracellular ATP, NAD Conclusion: This approach enables predictive, multiplexed metabolic profiling using minimal sample input and offers a scalable strategy to optimize T-cell manufacturing for memory enrichment and cytotoxic potency.

Indexed as

Cell Culture TechniquesLymphocyte ActivationT-LymphocytesAdenosine TriphosphateCell ProliferationCells, CulturedCulture MediaGlycolysisHumansAdenosine TriphosphateCulture Mediaadoptive cell therapybioluminescent assaysex vivo expansionglycolysisimmunometabolismmemory T cellsmetabolic profilingT cell metabolism

Identifiers

PMID41280912
PMCPMC12631338

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.